Not Signed In -
Atelosteogenesis, type 2 |
AO2; De la Chapelle dysplasia; McAlister dysplasia; Neonatal osseous dysplasia 1 |
Clinical Trial: Efficacy and Safety of Vildagliptin in Patients with Type 2 Diabetes
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to determine the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to the safety and effectiveness of a marketed drug when added to another marketed drug for type 2 diabetes.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Diabetes Mellitus, Type 2 | Drug: vildagliptin | Phase III |
MedlinePlus related topics: Diabetes
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Further Study Details:
Primary Outcomes: Blood glucose levels
Study start: March 2005
Eligibility
Ages Eligible for Study: 18 Years - 73 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
- Pregnancy or lactation
- Type 1 diabetes
- Evidence of significant diabetic complications
Location and Contact Information
New Jersey
Novartis Pharmaceuticals, East Hanover, New Jersey, 07936, United States; Recruiting
Customer Information Center 862-778-8300
More Information
Novartis patient recruitment website
Study ID Numbers: CLAF237A2308
Record last reviewed: March 2005
Last Updated: March 22, 2005
Record first received: March 22, 2005
ClinicalTrials.gov Identifier: NCT00106340
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: March 2005
Last Updated: March 22, 2005
Record first received: March 22, 2005
ClinicalTrials.gov Identifier: NCT00106340
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
